Elixion Biotech
Elixion Biotech is a precision-medicine drug discovery company whose R&D platform integrates quantum physics, causal biology, multi-omics data and native AI for early-stage drug target discovery.
Position in SVTRnew
Snapshot 2026-11-03- Startup SignalsRankedof 2,280
- Life SciencesRankedof 240
- Drug DiscoveryRankedof 68
About
Elixion Biotech is a precision-medicine drug discovery company whose R&D platform integrates quantum physics, causal biology, multi-omics data and native AI for early-stage drug target discovery. Its first validation program targeted breast cancer (HER2-negative and triple-negative subtypes), completing in-silico validation of five therapeutic targets within about eleven months — recovering established biomarkers (HER2/ERBB2, ESR1, BRCA1, BRCA2) while also identifying new candidate targets and pathways. The company is now advancing toward wet-lab validation and preclinical translation.
Capital graph
Founders / team· 3
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Elixion Biotech
Elixion Biotech is a precision-medicine drug discovery company whose R&D platform integrates quantum physics, causal biology…
—
United States
BusinessLatest roundTotal raisedDate- RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional m…
Seed · $14M · 2026-03
$14M - Neomera BioLab
AI-driven peptide/biologics drug discovery platform targeting hard-to-drug membrane protein targets such as GPCRs and ion channels…
— - Apricity Health
Tech-driven virtual oncology care platform plus Dynamic Precision real-world data drug discovery engine, integrating patient-reported outcomes…
—
China
BusinessLatest roundTotal raisedDate- LattixOrigin
Cross-scale human brain foundation model for drug target discovery in neurodegenerative diseases
Seed · 2026-10
— - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design…
Series D+ · $210M · 2025-03
$210M - Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing…
—
Europe
BusinessLatest roundTotal raisedDate- Aqemia
Cancer drug discovery using generative AI and quantum physics
Undisclosed · $71M · 2024-12
$71M - OutSee
AI analysis of individual genomes to predict disease biology and help drug developers find new targets
Seed · $2M · 2025-06
$2M - Relation Therapeutics
Multi-omics plus active graph machine learning to discover and validate novel drug targets, partnered with GSK (fibrosis and osteoarthritis)
Undisclosed · $61M · 2025-12
$61M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health.
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.